Drug Approval | March 28, 2022
EU approves Evusheld to prevent Covid-19
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Evusheld significantly reduced the risk of developing symptomatic COVID-19 in PROVENT Phase III trial, with protection lasting at least six months
Vela Analytics can create concise, evidence-based in-house reports that help customers with the information to make timely, informed decisions about possible treatment options
It celebrated its 100th session as LPC-100 in association with Mundial Pharma
Clinical trials for minimally invasive therapy procedures using advanced imaging from Philips Lung Suite start with successful first cases
The fund will take equity positions in India-focused healthcare and life sciences-related companies
Registration is open for the global event that invites technology enthusiasts to bring innovative ideas to improve healthcare outcomes
Veritaz has over 40 brands marketed across the acute and critical care therapeutic segments
The company’s differentiated value proposition comes during a time of unprecedented disruption in the life science supply chain
There are currently no approved systemic treatments for prurigo nodularis; regulatory filings for prurigo nodularis planned in the first half of 2022
The MoU proposed investments in hospitals, pharmacies and laboratories in the state
Subscribe To Our Newsletter & Stay Updated
